Coherus Oncology is currently navigating a high-risk transition from a legacy biosimilar business to a focused oncology pipeline, a shift that has resulted in a dramatic revenue contraction from $91.5M in 2023Q4 to $12.3M in 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.19+24.0% vs -$0.25 | $14M-0.7% vs $14M |
Q2 2026 May 11, 2026 | -$0.25+5.1% vs -$0.26 | $12M-13.4% vs $14M |
Q2 2026 Mar 9, 2026 | -$0.34+4.2% vs -$0.36 | $13M-8.4% vs $14M |
Q4 2025 Nov 6, 2025 | -$0.33-3.1% vs -$0.32 | $12M-17.9% vs $14M |
Coherus Oncology (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer Transcript
Coherus Oncology NASDAQ: CHRS presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several solid-tumor settings. The company highlighted early activity in esophageal squamous cell carcinoma, or ESCC, and said it plans to expand cohorts and discuss potential regulatory paths with the U.S. Food and Drug Administration.
- 1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients- -2L ESCC durable clinical benefit observed with a clear dose-response irrespective of PD-L1 status and in PD-1 refractory patients- - Anti-tumor activity demonstrated across five indications and over 120 patients, including HPV-positive head and neck and GI tumors- - Acceptable and manageable safety profile, with no new safety signals to date supports continued development- - Company to host a webcast today at 4:30 pm EDT- REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced interim clinical data from the TREGCHECK™ development program evaluating tagmokitug, its investigational cytolytic CCR8 antibody, in combination with toripalimab, with or without chemotherapy.
Benchmark CHRS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Coherus Oncology, Inc. (CHRS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.77 | $94.26M | -0.91 | -84.2% | -257.1% | -181.73% | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $20.14 | $6.43B | 45.82 | 8.05% | 4.62% | 82.23% | — | |
| $15.16 | $2.64B | 148.05 | -12.73% | 3.26% | 1.42% | — | |
| $59.83 | $9.16B | 21.31 | 87.32% | 55.22% | 72.3% | — | |
| $2.33 | $148.1M | -10.15 | 0.78% | -8.7% | -31.27% | — |
Coherus Oncology, Inc. (CHRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Coherus Oncology, Inc. (CHRS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 15, 2026·SEC
Jun 1, 2026·SEC
Get notified when CHRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Coherus Oncology, Inc. (CHRS) stock FAQ — growth, dividends, profitability & financials explained
Coherus Oncology, Inc. (CHRS) reported $50.9M in revenue over the trailing twelve months. Revenue was $42.2M in fiscal year 2025. That is 2121% more than the $1.9M of fiscal year 2012.
Coherus Oncology, Inc. (CHRS) revenue fell by 64.3% over the trailing twelve months, compared with the twelve months before.
No. Coherus Oncology, Inc. (CHRS) reported a net loss of $131.0M over the trailing twelve months.
Coherus Oncology, Inc. (CHRS) had a return on equity (ROE) of -181.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Coherus Oncology, Inc. (CHRS) had negative free cash flow of $243.9M over the trailing twelve months.
